Lyell Immunopharma, Inc.

Lyell Immunopharma develops chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies and solid tumors. The company employs proprietary engineering approaches including c-Jun overexpression, NR4A3 gene knockout, and CD62L positive enrichment to enhance CAR T-cell function and reduce exhaustion. Its lead candidate, IMPT-314, is a dual-targeting CD19/CD20 CAR T-cell product in Phase 1/2 development for patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma. The company is also advancing a solid tumor program through preclinical development.

Lyell's pipeline incorporates multiple proprietary platforms, including Epi-R, designed to generate stem-like T cells with improved proliferation and antitumor activity, and Stim-R, a synthetic-cell mimetic approach. These platforms represent the company's core technology for cell therapy development.

Based in South San Francisco, California, Lyell operates as a clinical-stage company with approximately 300 full-time employees. The company was incorporated in Delaware in 2018 and is publicly traded on the Nasdaq. As a preclinical and early clinical-stage entity, the company does not generate significant revenue from product sales.